touchPODCAST

Extending the benefit of PARP inhibitors through combinations for advanced prostate cancer - Conversation 3

touchMDT for touchONCOLOGY

Listen to a medical oncologist, a urologist and an oncology pharmacist discuss extending the benefit of PARP inhibitors through combinations for the treatment of advanced prostate cancer. 

The multidisciplinary team 

• Medical Oncologist: Dr Wassim Abida, USA
• Urologist: Professor Axel Merseburger, Germany
• Oncology Pharmacist: Dr Lisa Holle, USA

This touchPODCAST is for HCPs only.

This activity is funded by an independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/

 

PARP inhibitor combination clinical trials for advanced prostate cancer - Conversation 2

touchMDT for touchONCOLOGY

Listen to a urologist and a medical oncologist discuss key clinical trials investigating PARP inhibitor combinations for the treatment of advanced prostate cancer.

The multidisciplinary team 

• Urologist: Professor Axel Merseburger, Germany
• Medical Oncologist: Dr Wassim Abida, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/

Rationale for PARP inhibitor combinations for advanced prostate cancer - Conversation 1

touchMDT for touchONCOLOGY

Listen to an oncology pharmacist and a medical oncologist discuss the rationale for PARP inhibitors for the treatment of advanced prostate cancer. 

The multidisciplinary team 

• Oncology Pharmacist: Dr Lisa Holle, USA
• Medical Oncologist: Dr Wassim Abida, USA

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/

ENT experts discuss minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis

touchIN CONVERSATION for touchRESPIRATORY

Listen to Professor Valerie Lund in conversation with Dr Sietze Reitsma. They respond to questions submitted by the HCP audience and provide their expert insights on the key considerations for minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis.

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is provided by touchIME.

For further information visit our website:  https://www.touchrespiratory.com/cme/minimizing-the-clinical-burden-of-chronic-rhinosinusitis-with-nasal-polyposis/

ENT experts discuss minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis

touchIN CONVERSATION for touchIMMUNOLOGY

Listen to Professor Valerie Lund in conversation with Dr Sietze Reitsma. They respond to questions submitted by the HCP audience and provide their expert insights on the key considerations for minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis.

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is provided by touchIME.

For further information visit our website:  https://www.touchimmunology.com/cme/minimizing-the-clinical-burden-of-chronic-rhinosinusitis-with-nasal-polyposis/

Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion

touchPANEL DISCUSSION for touchNEUROLOGY

Listen as three experts in spinal muscular atrophy (SMA) discuss factors influencing treatment decision-making with approved SMA therapies using patient case studies.

The experts

• Prof. Eugenio Mercuri – Policlinico Universitario Agostino Gemelli, Rome, Italy
• Prof. Nathalie Goemans – UZ Leuven, Leuven, Belgium
• Prof. Dr. med. Tim Hagenacker – Essen University Hospital, Essen, Germany

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Biogen and Novartis Gene Therapies. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurology.com/cme/selecting-disease-modifying-treatments-in-sma/

Improving patient outcomes in relapsing MS: Current oral DMTs and emerging therapies

touchTALKS for touchNEUROLOGY 

Listen to a leading expert in multiple sclerosis (MS) discuss how disease-modifying therapies are currently used in clinical practice for the optimal management of relapsing MS. Prof. Patricia K Coyle highlights the importance of reducing the burden of the often ‘invisible’ symptoms of MS, such as fatigue, on overall patient quality of life, and reviews the latest, potentially practice-changing developments, which could further improve patient outcomes through shared treatment decision making.  

The expert

• Prof. Patricia K Coyle, MS Comprehensive Care Center, Stony Brook University Hospital, Stony Brook, NY, USA

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent medical education grant from Janssen Pharmaceutica NV. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchneurology.com/cme/dmts-in-rms/ 

PARP inhibitors as first-line maintenance therapy in ovarian cancer: Update from SGO 2022

touchCONGRESS for touchONCOLOGY

Listen to Prof. Isabelle Ray-Coquard (France) cover key data presented at SGO 2022 on PARP inhibitors as first-line maintenance therapy in ovarian cancer, and their implications for clinical practice, including expert insights and interpretation from Dr Antonio González-Martín (Spain) and Dr Sandro Pignata (Italy).

OVERVIEW

• Data review with Prof. Ray-Coquard (0:32)
• Expert interviews with Dr González-Martín, Dr Pignata and
  Prof. Ray-Coquard, answering the questions below

INTERVIEW QUESTIONS

1. 1. How have the clinical trial data regarding first-line maintenance with PARP inhibitors in patients with ovarian cancer changed our understanding of the efficacy of these treatments? (22:56)
   2. What have we learned about managing adverse events in patients with ovarian cancer receiving first-line maintenance with PARP inhibitors? (29:21)
   3. Based on the presentations at SGO 2022, are you likely to change how you personalize treatment by considering the patient’s molecular characteristics? (36:32)
   4. What can we learn from the real-world evidence for first-line maintenance with PARP inhibitors presented at SGO 2022? (43:15)
   5. How do you see the role and optimization of PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer evolving in the next 5 years? (49:39)

This touchPODCAST is for HCPs only. 

This activity is funded by an unrestricted independent medical education grant from GlaxoSmithKline. This activity is provided by touchIME.

For further information visit our website: https://touchoncology.com/education/parp-inhibitors-maintenance-sgo2022/

MDT and patient perspectives on the role of GLP-1 RAs in the T2D management pathway

touchMDT for touchENDOCRINOLOGY

Listen to key experts from a multidisciplinary team and a patient explore the role of GLP-1 RAs in the T2D management pathway, real-world factors affecting selection of a GLP-1 RA, and how GLP-1 RA therapy has influenced real-life patients in their glycemic and weight-loss goals

The multidisciplinary team and patient

• Endocrinologist: Prof. Dr med. Michael Nauck, Bochum, Germany
• Primary Care Physician: Dr Kevin Fernando, Berwick, UK
• Patient Advocate: Ms Kelly Ann Hardy, Margate, UK

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchendocrinologyime.org/mdt-integrating-glp1ras-t2d-management-from-pcp-to-patient/

MDT and patient perspectives on the safety of GLP-1 RAs and managing their side effects

touchMDT for touchENDOCRINOLOGY

Listen to key experts from a multidisciplinary team and a patient explore the safety of GLP-1 RAs and the role of patient education in managing the side effects of these agents

The multidisciplinary team and patient

• Primary Care Physician: Dr Kevin Fernando, Berwick, UK
• Diabetes Nurse Specialist: Prof. Dr Şeyda Özcan, Istanbul, Turkey
• Patient Advocate: Ms Kelly Ann Hardy, Margate, UK

This touchPODCAST is for HCPs only.

This activity is funded by an unrestricted independent medical education grant from Novo Nordisk A/S. This activity is jointly provided by USF Health and touchIME.

For further information visit our website: https://touchendocrinologyime.org/mdt-integrating-glp1ras-t2d-management-from-pcp-to-patient/